#151863

Anti-Cytochrome P450 3A5 [F18P3B6]

Cat. #151863

Anti-Cytochrome P450 3A5 [F18P3B6]

Cat. #: 151863

Sub-type: Primary antibody

Unit size: 100 ug

Target: CYP3A5- Cytochrome P450 3A5 (EC 1.14.14.1) (niphedipine oxidase), (CYPIIIA5) (P450-PCN3) (HLp2).

Class: Monoclonal

Application: IHC ; WB ; ELISA ; IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ayham Alnabulsi

Institute: Vertebrate Antibodies Limited

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Cytochrome P450 3A5 [F18P3B6]
  • Research fields: Cancer;Cell signaling and signal transduction;Metabolism;Tissue-specific biology
  • Clone: F18P3B6
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; WB ; ELISA ; IHC ; WB
  • Description: This monoclonal antibody (MAb), when used in conjunction with the MAb specific to CYP3A7 clone F19 P2 H2, is able to differentiate between the CYP450 family 3 members: CYP3A5 and CYP3A7.
  • Immunogen: Ovalbumin-conjugated synthetic peptide DSRDGTLSGE (C-terminal sequence)
  • Isotype: IgG1 kappa
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: IHC: formalin-fixed, paraffin-embedded squamous oesophagus cancer sections western blot: recombinant P450 (shown below @ 0.5 pmol per lane).

Target Details

  • Target: CYP3A5- Cytochrome P450 3A5 (EC 1.14.14.1) (niphedipine oxidase), (CYPIIIA5) (P450-PCN3) (HLp2).
  • Tissue cell line specificity: IHC: formalin-fixed, paraffin-embedded squamous oesophagus cancer sections western blot: recombinant P450 (shown below @ 0.5 pmol per lane).
  • Target background: This monoclonal antibody (MAb), when used in conjunction with the MAb specific to CYP3A7 clone F19 P2 H2, is able to differentiate between the CYP450 family 3 members: CYP3A5 and CYP3A7.

Applications

  • Application: IHC ; WB ; ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Zia et al. 2015. Int J Exp Pathol. 96(2):81-6. PMID: 25670065.
  • CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
  • Murray et al. 2010. Histopathology. 57(2):202-11. PMID: 20716162.
  • Profiling the expression of cytochrome P450 in breast cancer.
  • Downie et al. 2005. Clin Cancer Res. 11(20):7369-75. PMID: 16243809.
  • Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
  • Kumarakulasingham et al. 2005. Clin Cancer Res. 11(10):3758-65. PMID: 15897573.
  • Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.
  • Kosik et al. 1992. Science. 256(5058):780-3. PMID: 1589757.
  • Alzheimer's disease: a cell biological perspective.